119P: Real-world first-line (1L) treatment characteristics and physician-reported areas of improvement for patients with advanced non-small cell lung cancer (aNSCLC) with PD-L1 expression ≥50% and without actionable genomic alternations (AGA) in Europe (EU), United States (US) and Asia | Publicación